Global Pneumonia Vaccines Market to reach a market size of $9.6 billion by 2025 - KBV Research

According to a new report Global Pneumonia Vaccines Market, published by KBV research, The Global Pneumonia Vaccines Market size is expected to reach $9.6 billion by 2025, rising at a market growth of 5.1% CAGR during the forecast period.

The North America market dominated the Global Pneumococcal Conjugate Vaccine (PCV) Market by Region in 2018, growing at a CAGR of 2.8 % during the forecast period. The Europe market is expected to witness a CAGR of 3.6% during (2019 - 2025). Additionally, The Asia Pacific market is expected to witness a CAGR of 5.3% during (2019 - 2025).

The Prevnar 13 market dominated the Global Pneumonia Vaccines Market by Product Type in 2018, growing at a CAGR of 4.1 % during the forecast period. The Synflorix market is expected to witness a CAGR of 7.5% during (2019 - 2025). Additionally, The Pneumovax23 market is expected to witness highest CAGR of 8.5% during (2019 - 2025).

The Distribution Partner Companies market dominated the Global Pneumonia Vaccines Market by Distribution Channel in 2018, growing at a CAGR of 4.3 % during the forecast period. The Non-Governmental Organizations (NGO) market is expected to witness a CAGR of 6% during (2019 - 2025).

Full Report: https://www.kbvresearch.com/pneumonia-vaccines-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. and MERCK & CO., Inc.

Global Pneumonia Vaccines Market Segmentation

By Vaccine Type

• Pneumococcal conjugate vaccine (PCV)
• Pneumococcal polysaccharide vaccine (PPSV/PPV)

By Product Type

• Prevnar 13
• Synflorix
• Pneumovax23

By Sector

• Public sector
• Private sector

By Distribution Channel

• Distribution partner companies
• Non-governmental Organizations (NGO)
• Government Authorities

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Glaxosmithkline Plc. (GSK)
• LG Corporation
• Panacea Biotec Limited
• Pfizer, Inc.
• Pnuvax Incorporated
• Poonawalla Investments & Industries Pvt. Ltd.
• Shenzhen Kangtai Biological Products Co., Ltd.
• SK Holdings Co., Ltd.
• Walvax Biotechnology Co., Ltd.
• Merck & Co., Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Pneumonia Vaccines Market Related Reports:

North America Market

Europe Market

Asia Pacific Market

LAMEA Market